{"name":"Remegen","slug":"remegen","ticker":"9995.HK","exchange":"HKEX","domain":"remegen.com","description":"RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug fo","hq":"Yantai, China","founded":0,"employees":"3048","ceo":"","sector":"ADC / HER2","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":89.95,"stockChange":-2.55,"stockChangePercent":-2.76,"marketCap":"$7.9B","metrics":{"revenue":498341521.4279859,"revenueGrowth":24.8,"grossMargin":86.9,"rdSpend":0,"netIncome":190387968.5670989,"cash":404614261.6546099,"dividendYield":0,"peRatio":60.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"Telitacicept Freeze-dried powder Injection 80mg","genericName":"Telitacicept Freeze-dried powder Injection 80mg","slug":"telitacicept-freeze-dried-powder-injection-80mg","indication":"Other","status":"marketed"},{"name":"Furmonertinib Mesilate Tablets Monotherapy","genericName":"Furmonertinib Mesilate Tablets Monotherapy","slug":"furmonertinib-mesilate-tablets-monotherapy","indication":"Other","status":"phase_2"},{"name":"Placebo plus standard therapy","genericName":"Placebo plus standard therapy","slug":"placebo-plus-standard-therapy","indication":"Other","status":"marketed"},{"name":"RC108","genericName":"RC108","slug":"rc108","indication":"Other","status":"phase_2"},{"name":"RC118","genericName":"RC118","slug":"rc118","indication":"Other","status":"phase_1"},{"name":"RC148","genericName":"RC148","slug":"rc148","indication":"Other","status":"phase_2"},{"name":"RC148 Monotherapy","genericName":"RC148 Monotherapy","slug":"rc148-monotherapy","indication":"Other","status":"phase_1"},{"name":"RC278","genericName":"RC278","slug":"rc278","indication":"Other","status":"phase_1"},{"name":"RC48-ADC in Combination with gemcitabine","genericName":"RC48-ADC in Combination with gemcitabine","slug":"rc48-adc-in-combination-with-gemcitabine","indication":"Other","status":"phase_2"},{"name":"RC88","genericName":"RC88","slug":"rc88","indication":"Other","status":"phase_2"},{"name":"RC98","genericName":"RC98","slug":"rc98","indication":"Other","status":"phase_1"},{"name":"Sequential CTX","genericName":"Sequential CTX","slug":"sequential-ctx","indication":"Other","status":"phase_2"},{"name":"Sequential Epirubicin","genericName":"Sequential Epirubicin","slug":"sequential-epirubicin","indication":"Other","status":"phase_2"},{"name":"Toripalimab （12weeks）","genericName":"Toripalimab （12weeks）","slug":"toripalimab-12weeks","indication":"Other","status":"phase_2"},{"name":"Toripalimab （18weeks）","genericName":"Toripalimab （18weeks）","slug":"toripalimab-18weeks","indication":"Other","status":"phase_2"},{"name":"intravitreal injection of RC28-E","genericName":"intravitreal injection of RC28-E","slug":"intravitreal-injection-of-rc28-e","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"Disitamab Vedotin for injection","genericName":"Disitamab Vedotin for injection","slug":"disitamab-vedotin-for-injection","indication":"Locally advanced or metastatic non-small cell lung cancer","status":"phase_2"},{"name":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","slug":"disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine","indication":"HER2-positive gastric or gastroesophageal junction cancer (phase 3)","status":"phase_3"},{"name":"Pertuzumab Injection","genericName":"Pertuzumab Injection","slug":"pertuzumab-injection","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"RC-28E","genericName":"RC-28E","slug":"rc-28e","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"RC148 plus Carboplatin and Paclitaxel","genericName":"RC148 plus Carboplatin and Paclitaxel","slug":"rc148-plus-carboplatin-and-paclitaxel","indication":"Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)","status":"phase_3"},{"name":"Tislelizumab plus Carboplatin and Paclitaxel","genericName":"Tislelizumab plus Carboplatin and Paclitaxel","slug":"tislelizumab-plus-carboplatin-and-paclitaxel","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Albumin-bound Paclitaxone","genericName":"Albumin-bound Paclitaxone","slug":"albumin-bound-paclitaxone","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Disitamab Vedotin Injection","genericName":"Disitamab Vedotin Injection","slug":"disitamab-vedotin-injection","indication":"Locally advanced or metastatic gastric adenocarcinoma","status":"phase_2"},{"name":"Disitamab Vedotin Injection （18 weeks）","genericName":"Disitamab Vedotin Injection （18 weeks）","slug":"disitamab-vedotin-injection-18-weeks","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_2"},{"name":"RC28-E","genericName":"RC28-E","slug":"rc28-e","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"RC48-ADC","genericName":"RC48-ADC","slug":"rc48-adc","indication":"HER2-positive gastric cancer","status":"phase_3"}]}],"pipeline":[{"name":"Disitamab Vedotin for injection","genericName":"Disitamab Vedotin for injection","slug":"disitamab-vedotin-for-injection","phase":"phase_2","mechanism":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells.","indications":["Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","slug":"disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine","phase":"phase_3","mechanism":"This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage.","indications":["HER2-positive gastric or gastroesophageal junction cancer (phase 3)"],"catalyst":""},{"name":"Pertuzumab Injection","genericName":"Pertuzumab Injection","slug":"pertuzumab-injection","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"RC-28E","genericName":"RC-28E","slug":"rc-28e","phase":"phase_3","mechanism":"RC-28E is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"RC148 plus Carboplatin and Paclitaxel","genericName":"RC148 plus Carboplatin and Paclitaxel","slug":"rc148-plus-carboplatin-and-paclitaxel","phase":"phase_3","mechanism":"RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy.","indications":["Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)"],"catalyst":""},{"name":"Telitacicept Freeze-dried powder Injection 80mg","genericName":"Telitacicept Freeze-dried powder Injection 80mg","slug":"telitacicept-freeze-dried-powder-injection-80mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tislelizumab plus Carboplatin and Paclitaxel","genericName":"Tislelizumab plus Carboplatin and Paclitaxel","slug":"tislelizumab-plus-carboplatin-and-paclitaxel","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Albumin-bound Paclitaxone","genericName":"Albumin-bound Paclitaxone","slug":"albumin-bound-paclitaxone","phase":"phase_2","mechanism":"Albumin binding enhances the solubility of paclitaxel, allowing for higher doses to be administered.","indications":["Non-small cell lung cancer","Breast cancer","Ovarian cancer"],"catalyst":""},{"name":"Disitamab Vedotin Injection","genericName":"Disitamab Vedotin Injection","slug":"disitamab-vedotin-injection","phase":"phase_2","mechanism":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor.","indications":["Locally advanced or metastatic gastric adenocarcinoma","Locally advanced or metastatic esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Disitamab Vedotin Injection （18 weeks）","genericName":"Disitamab Vedotin Injection （18 weeks）","slug":"disitamab-vedotin-injection-18-weeks","phase":"phase_2","mechanism":"Anti-CD6 monoclonal antibody","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Furmonertinib Mesilate Tablets Monotherapy","genericName":"Furmonertinib Mesilate Tablets Monotherapy","slug":"furmonertinib-mesilate-tablets-monotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo plus standard therapy","genericName":"Placebo plus standard therapy","slug":"placebo-plus-standard-therapy","phase":"marketed","mechanism":"Placebo plus standard therapy provides no active pharmacological intervention beyond the standard treatment already being administered.","indications":[],"catalyst":""},{"name":"RC108","genericName":"RC108","slug":"rc108","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC118","genericName":"RC118","slug":"rc118","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC148","genericName":"RC148","slug":"rc148","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC148 Monotherapy","genericName":"RC148 Monotherapy","slug":"rc148-monotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC278","genericName":"RC278","slug":"rc278","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC28-E","genericName":"RC28-E","slug":"rc28-e","phase":"phase_3","mechanism":"RC28-E is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"RC48-ADC","genericName":"RC48-ADC","slug":"rc48-adc","phase":"phase_3","mechanism":"RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor.","indications":["HER2-positive gastric cancer","HER2-positive breast cancer","HER2-positive biliary tract cancer"],"catalyst":""},{"name":"RC48-ADC in Combination with gemcitabine","genericName":"RC48-ADC in Combination with gemcitabine","slug":"rc48-adc-in-combination-with-gemcitabine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC88","genericName":"RC88","slug":"rc88","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RC98","genericName":"RC98","slug":"rc98","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sequential CTX","genericName":"Sequential CTX","slug":"sequential-ctx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sequential Epirubicin","genericName":"Sequential Epirubicin","slug":"sequential-epirubicin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Toripalimab （12weeks）","genericName":"Toripalimab （12weeks）","slug":"toripalimab-12weeks","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Toripalimab （18weeks）","genericName":"Toripalimab （18weeks）","slug":"toripalimab-18weeks","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intravitreal injection of RC28-E","genericName":"intravitreal injection of RC28-E","slug":"intravitreal-injection-of-rc28-e","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":27,"phaseCounts":{"phase_2":14,"phase_3":7,"marketed":2,"phase_1":4},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":477746850.3612,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":477746850.3612},{"period":"2024-12-31","value":252045228.72904},{"period":"2023-12-31","value":158601944.1501},{"period":"2022-12-31","value":113156038.46175}],"grossProfit":415035170.31735,"grossProfitHistory":[{"period":"2025-12-31","value":415035170.31735},{"period":"2024-12-31","value":201523347.50011998},{"period":"2023-12-31","value":121294312.41938},{"period":"2022-12-31","value":73371950.84972}],"rdSpend":179621384.80573,"rdSpendHistory":[{"period":"2025-12-31","value":179621384.80573},{"period":"2024-12-31","value":226935207.04705998},{"period":"2023-12-31","value":192525837.82339},{"period":"2022-12-31","value":144740688.6816}],"sgaSpend":217223485.31291,"operatingIncome":23042550.212419998,"operatingIncomeHistory":[{"period":"2025-12-31","value":23042550.212419998},{"period":"2024-12-31","value":-202035057.00555998},{"period":"2023-12-31","value":-221418412.63242},{"period":"2022-12-31","value":-155352028.73983}],"netIncome":104589473.08049999,"netIncomeHistory":[{"period":"2025-12-31","value":104589473.08049999},{"period":"2024-12-31","value":-216409790.56074},{"period":"2023-12-31","value":-222727604.89532998},{"period":"2022-12-31","value":-147209333.32909998}],"eps":-2.73,"epsHistory":[{"period":"2024-12-31","value":-2.73},{"period":"2023-12-31","value":-2.8},{"period":"2022-12-31","value":-1.88},{"period":"2021-12-31","value":0.57}],"cash":170166844.26023,"cashHistory":[{"period":"2025-12-31","value":170166844.26023},{"period":"2024-12-31","value":111940875.7681},{"period":"2023-12-31","value":107080519.75704},{"period":"2022-12-31","value":304959410.8486}],"totalAssets":1068233680.4474399,"totalLiabilities":536359106.47249997,"totalDebt":324491769.44493,"equity":531874573.97494,"operatingCashflow":7714256.605339999,"operatingCashflowHistory":[{"period":"2025-12-31","value":7714256.605339999},{"period":"2024-12-31","value":-173408801.05492},{"period":"2023-12-31","value":-221342216.25733},{"period":"2022-12-31","value":-186244721.54953}],"capex":-29477238.29062,"capexHistory":[{"period":"2025-12-31","value":-29477238.29062},{"period":"2024-12-31","value":-39097730.709139995},{"period":"2023-12-31","value":-125678183.16803},{"period":"2022-12-31","value":-111644196.26509}],"freeCashflow":-21762981.68528,"dividendsPaid":null,"buybacks":null,"employees":3048,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":89.95,"previousClose":92.5,"fiftyTwoWeekHigh":126.6,"fiftyTwoWeekLow":39.25,"fiftyTwoWeekRange":"39.25 - 126.6","fiftyDayAverage":100.09,"twoHundredDayAverage":90.39,"beta":0.48,"enterpriseValue":7401279961.054781,"forwardPE":56.9,"priceToBook":11.24,"priceToSales":15.85,"enterpriseToRevenue":14.85,"enterpriseToEbitda":83.88,"pegRatio":0,"ebitda":88241762.17235903,"ebitdaMargin":17.7,"freeCashflow":137548911.06239745,"operatingCashflow":37226427.912612475,"totalDebt":308675077.41220737,"debtToEquity":53.3,"currentRatio":1.58,"returnOnAssets":3.4,"returnOnEquity":45.3,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":15,"targetMeanPrice":111.72,"targetHighPrice":144.61,"targetLowPrice":52.87,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.4,"institutionHeldPercent":28.2,"sharesOutstanding":208581239,"floatShares":348614999,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.49,"epsForward":1.58,"revenuePerShare":6.11,"bookValue":8,"officers":[{"age":66,"name":"Mr. Weidong  Wang","title":"Co-Founder & Executive Chairman"},{"age":63,"name":"Dr. Jianmin  Fang","title":"Co-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director"},{"age":54,"name":"Mr. Shaojing  Tong","title":"CFO & Joint Company Secretary"},{"age":70,"name":"Mr. Jian  Lin","title":"Executive Director"},{"age":59,"name":"Mr. Qingkai  Wen","title":"Executive Director & Board Secretary"},{"age":null,"name":"Mr. Kaisheng  Huang","title":"Chief Operating Officer"},{"age":null,"name":"Dr. Marie  Zhu","title":"Chief Technical Officer"},{"age":null,"name":"Dr. Zhulun  Wang","title":"Chief Scientific Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.remegen.com","phone":"86 53 5611 3511"}}